EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kidswell Bio's EBITDA for the
six
months ended in Mar. 2026 was 円-459 Mil. Kidswell Bio's Revenue for the
six
months ended in Mar. 2026 was 円3,314 Mil. Therefore, Kidswell Bio's EBITDA margin for the quarter that ended in Mar. 2026 was -13.85%.
Kidswell Bio (TSE:4584) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kidswell Bio EBITDA Margin % Related Terms
Kidswell Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kidswell Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4584 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Kidswell Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kidswell Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kidswell Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kidswell Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kidswell Bio (TSE:4584) has a EBITDA Margin % of -13.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kidswell Bio and its competitors. According to the industry distribution chart, Kidswell Bio ranks #330 out of 938 companies in the Biotechnology industry, placing it in the top 35.2%.
Is Kidswell Bio's EBITDA Margin % too high?
Kidswell Bio's current EBITDA Margin % is -13.85%. Based on the distribution chart, Kidswell Bio ranks #330 out of 938 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kidswell Bio has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kidswell Bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kidswell Bio ranks #330 out of 938 companies for EBITDA Margin %. This puts Kidswell Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kidswell Bio and its competitors. Kidswell Bio's current EBITDA Margin % is -13.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kidswell Bio stock overvalued right now?
Based on GuruFocus' analysis, Kidswell Bio (TSE:4584) is currently considered Possible Value Trap. The stock's GF Value™ is 円233.48, compared to a current price of 円156.00 — trading 33.2% below its estimated fair value. The current EBITDA Margin % is -13.85%. Kidswell Bio's overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kidswell Bio (TSE:4584), the current EBITDA Margin % is -13.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kidswell Bio (TSE:4584) Overvalued in 2026?
Based on GuruFocus' analysis, Kidswell Bio stock appears to be undervalued.
The current stock price of 円156.00 is trading 33.2% below its estimated GF Value™ of 円233.48.
GuruFocus considers Kidswell Bio to be Possible Value Trap.
Key valuation signals for TSE:4584:
EBITDA Margin %: -13.85%
GF Value™: 円233.48 vs. price of 円156.00 (33.2% below fair value)
No single metric tells the full story. See the TSE:4584 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4584 has been successfully added to your 
